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Myeloid suppressor cells (MSCs) producing high levels of arginase I block T cell function by 
depleting 
 
L
 
-arginine in cancer, chronic infections, and trauma patients. In cancer, MSCs 
infiltrating tumors and in circulation are an important mechanism for tumor evasion and 
impair the therapeutic potential of cancer immunotherapies. However, the mechanisms that 
induce arginase I in MSCs in cancer are unknown. Using the 3LL mouse lung carcinoma, we 
aimed to characterize these mechanisms. Arginase I expression was independent of T cell–
produced cytokines. Instead, tumor-derived soluble factors resistant to proteases induced and 
maintained arginase I expression in MSCs. 3LL tumor cells constitutively express cyclooxygenase 
(COX)-1 and COX-2 and produce high levels of PGE
 
2
 
. Genetic and pharmacological inhibition 
of COX-2, but not COX-1, blocked arginase I induction in vitro and in vivo. Signaling 
through the PGE
 
2
 
 receptor E-prostanoid 4 expressed in MSCs induced arginase I. Furthermore, 
blocking arginase I expression using COX-2 inhibitors elicited a lymphocyte-mediated 
antitumor response. These results demonstrate a new pathway of prostaglandin-induced 
immune dysfunction and provide a novel mechanism that can help explain the cancer 
prevention effects of COX-2 inhibitors. Furthermore, an addition of arginase I represents a 
clinical approach to enhance the therapeutic potential of cancer immunotherapies.
 
T cell anergy is a common observation in
patients and rodents with cancer. This tumor-
induced phenomenon may help tumors evade
the immune response and block the potential
therapeutic benefit of immunotherapy. Of the
several mechanisms described to explain anergy,
the accumulation of myeloid suppressor cells
(MSCs) in the tumor, spleen, and peripheral
blood of tumor-bearing mice and cancer patients
has gained considerable interest (1–6). Using
the 3LL murine lung carcinoma, we recently
demonstrated that 
 
L
 
-arginine (
 
L
 
-Arg) depletion in
the microenvironment by arginase I–producing
MSCs inhibited T cell receptor CD3
 

 
 expression
and blocked T cell functions (5). However, the
mechanisms that induce arginase I in MSCs in
cancer are unclear.
In vitro models show that cytokines such as
IL-4, IL-10, and IL-13 can induce the expression
of arginase I in bone marrow and peritoneal
macrophages through activation of nuclear
transcription factor STAT6 (7, 8). Similarly,
arginase I can also be induced in macrophages
exposed to cAMP analogues, prostaglandin E
 
2
 
(PGE
 
2
 
), LPS, hypoxia, and other cytokines in-
cluding TGF
 

 
 
 
(9). However, the role of these
factors in the induction of arginase I in cancer
has not been determined. Using the 3LL lung
carcinoma model, we attempted to characterize
the mechanism of arginase I induction in MSCs.
The results failed to demonstrate the presence
of IL-4 or IL-13 in the tumor microenvironment
or a role for T cell–produced cytokines in the
induction of arginase I in MSCs. Instead, soluble
factors produced by 3LL tumors were essential to
induce and maintain arginase I production in
MSCs. Prostanoid production by 3LL cells, in-
cluding PGE
 
2
 
, induced arginase I expression in
MSCs by signaling through the E-prostanoid
(EP) 4 receptor. Genetic or pharmacological
inhibition of cyclooxygenase (COX)-2 blocked
arginase I expression and induced a T cell–
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mediated antitumor effect. This represents a novel mecha-
nism for prostaglandin-induced immune dysfunction and
may explain the cancer prevention effect of COX-2 inhibition.
 
RESULTS
Arginase I expression in tumor-infiltrating MSCs 
is dependent on tumor-derived factors
 
Increased arginase activity in cancer was thought to come
from tumor cells metabolizing 
 
L
 
-Arg to produce polyamines,
which are needed to sustain rapid cell proliferation (10).
However, our recent data showed that arginase I was pro-
duced by tumor-infiltrating MSCs (5). The mechanisms that
induce arginase I in MSC-infiltrating tumors are not clear. In
vitro models showed that arginase I can be induced in perito-
neal and bone marrow macrophages by IL-4 and IL-13,
which can be produced by some tumors, infiltrating T lym-
phocytes, or NKT cells (11–13). However, none of these cy-
tokines was detected via protein or RNA assays in 3LL cells
cultured in vitro or in single-cell suspensions of subcutaneous
3LL tumors (unpublished data). Furthermore, no significant
differences in arginase I expression were observed in 3LL tu-
mors excised from tumor-bearing SCID mice (C57BL/6-
 
Prkdc
 
scid
 
), which lack functional T and B cells, and wild-type
C57BL/6 mice (Fig. 1 A). In addition, MSC-infiltrating tu-
mors isolated from wild-type and C57BL/6-
 
Prkdc
 
scid
 
 mice ex-
pressed similar levels of arginase I (Fig. 1 B), suggesting that T
cells and T cell–produced cytokines were not responsible for
arginase I induction in MSCs.
We then tested whether tumor-derived factors might be
necessary to induce or sustain arginase I production in MSCs.
Purified MSCs obtained from 3LL tumors cultured in vitro in
standard tissue culture medium (RPMI 1640 which contains
1,000 
 

 
M arginine) lose arginase I expression after 24 h. How-
ever, if freshly isolated MSCs were cocultured in transwells
with 3LL cells or 3LL supernatants, they maintained arginase I
expression (Fig. 2 A) and arginase activity (not depicted). Fur-
thermore, the reintroduction of 3LL tumor cells into the cul-
ture of MSCs that had lost arginase I induced the re-expression
of arginase I within 48 h (Fig. 2 B). Similar results were ob-
tained using peritoneal macrophages from normal mice cocul-
tured with 3LL tumor cells or 3LL supernatants (Fig. 2 C).
We then tested whether 3LL cells produced cytokines that
induce arginase I. An extended RNase protection assay using
RNA isolated from cultured 3LL cells, and including IL-1a, IL-
1b, IL-1Ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-
11, IL-13, IL-15, MIF, LIF, SCF, G-CSF, macrophage CSF
(mCSF), vascular endothelial growth factor (VEGF), GM-CSF,
and IFN-
 

 
 only showed the expression of mCSF and VEGF
(Fig. S1 A, available at http://www.jem.org/cgi/content/full/
jem.20050715/DC1). However, culture of MSCs (Fig. S1 B)
or peritoneal macrophages (not depicted) with increasing con-
centrations of mCSF or VEGF failed to induce arginase I. In ad-
dition, treatment of 3LL supernatants with various proteases—
including V8 protease, chymotrypsin, trypsin, and proteinase
K—only slightly decreased its ability to induce arginase I in
MSCs or peritoneal macrophages (unpublished data), suggesting
that cytokines were unlikely to be the inducers of arginase I.
Figure 1. Expression of arginase I in tumor-infiltrating MSCs is 
independent of lymphocytes. (A) Single-cell suspensions from individual 
subcutaneous 3LL tumors excised from tumor-bearing C57BL/6 and C57BL/6 
Prkdcscid mice (n  15 per group) were tested for arginase I expression 
via Western blot analysis. Representative results of 10 tumors are shown. 
(B) Arginase I expression was tested in freshly isolated MSCs infiltrating 
individual 3LL tumors from C57BL/6 and C57BL/6 Prkdcscid tumor-bearing 
mice (n  15 per group). Representative results from 6 tumors are shown.
Figure 2. Arginase I expression in MSCs is induced by tumor-derived 
soluble factors. (A) MSCs (2  106) isolated from 3LL tumors were cultured 
alone or cocultured in transwells with 2  106 3LL cells or 3LL supernatants. 
Arginase I expression was tested via Western blot analysis at 24, 48, and 
72 h. (B) MSCs (2  106) were cultured for 24 h in regular RPMI-1640, 
which results in the loss of arginase 1 expression. They were then cultured 
in RPMI-1640 alone or cocultured in transwells with 3LL cells (2  106). 
Arginase I expression was tested at 24, 48, or 72 h afterward via Western 
blot analysis. (C) Peritoneal macrophages (2  106) from normal mice 
were cocultured in transwells with 3LL cells (2  106) or 3LL supernatants. 
Arginase I expression was tested via Western blot analysis. Results shown 
are representative of 3 experiments.
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Arginase I induction in MSCs by 3LL tumor cells 
is dependent on COX-2
 
COX-1 and COX-2 protein and messenger RNA (mRNA)
were found to be constitutively expressed in 3LL cells cul-
tured in vitro and freshly isolated 3LL tumors (Fig. 3, A and
B). Consequently, PGE
 
2
 
 was found in the supernatants of
3LL cultures (Fig. 3 C). PGE
 
2
 
 is generated by the metabo-
lism of PGH
 
2
 
 by three different PGE
 
2
 
 synthases (PGESs),
one of which is expressed as a cytosolic form (cPGES) and
two of which are microsomal-associated forms (mPGES-1
and -2). We found a high expression of mPGES-2 and
cPGES but only a minimal expression of mPGES-1 in 3LL
cells cultured in vitro and 3LL cells isolated from freshly ex-
cised tumors (Fig. 3 D).
PGE
 
2
 
 can induce arginase I in vitro in bone marrow–
derived macrophages (14, 15). Consistent with these obser-
vations, the addition of PGE
 
2
 
 at concentrations found in
3LL supernatants (10 ng/ml) maintained arginase I expres-
sion in MSCs isolated from 3LL tumors (Fig. S2, available at
http://www.jem.org/cgi/content/full/jem.20050715/DC1).
We then tested whether PGE
 
2
 
 produced by 3LL cells was
responsible for arginase I induction in MSCs. The addi-
tion of 10 
 

 
g/ml of anti-PGE
 
2
 
 antibody, but not isotype
control, partially prevented the up-regulation of arginase I
by 3LL supernatants (Fig. 4 A). Furthermore, the addition
of increasing concentrations of COX-2 inhibitor sc-58125
(16), but not COX-1 inhibitor FR122047 (17), into MSC-
3LL cocultures completely blocked the induction of argi-
nase I and arginase activity in MSCs (P
 
 
 

 
 0.0001) (Fig. 4, B
and C). Similar results were obtained using other cell lines,
including squamous cell carcinoma (SCC) VII (Fig. S3, avail-
able at http://www.jem.org/cgi/content/full/jem.20050715/
DC1). To further confirm the role of COX-2 in the induc-
tion of arginase I we transiently (for 72 h) silenced COX-1
or COX-2 expression in 3LL cells by transfection with chem-
ical designed small interfering RNA (siRNA)
 
 
 
(Fig. 5 A). MSCs
cocultured with COX-2–silenced 3LL cells did not express
arginase I and had a lower arginase activity, similar to MSCs
cultured in medium alone (Fig. 5, B and C). In contrast,
MSCs cocultured with 3LL transfected with COX-1 siRNA
or an irrelevant siRNA (negative control) expressed high lev-
els of arginase I and had a higher arginase activity (P 
 

 
 0.005)
(Fig. 5, B and C). Experiments were repeated using perito-
neal macrophages obtaining similar results (Fig. S4, available
at http://www.jem.org/cgi/content/full/jem.20050715/DC1).
These results support the hypothesis that prostanoids pro-
duced by 3LL tumor cells are responsible for the induction
of arginase I in MSCs.
Figure 3. 3LL cells and 3LL tumors express COX-1 and COX-2. 
3LL cells cultured in vitro and single-cell suspension from subcutaneous 
tumors were tested for COX-1 and COX-2 protein (A) and mRNA (B). White 
lines indicate that intervening lanes have been spliced out. (C) Supernatants 
from 3LL cultured in vitro for 24 h were tested for PGE2 levels. (D) Cyto-
plasmic extracts from 3LL cells were also tested for PGES isoforms via 
Western blot analysis. Representative data are shown of experiments 
repeated three times.
Figure 4. Arginase I induction in MSCs by 3LL tumor cells is 
dependent on COX-2. (A) MSCs (2  106) were cultured in RPMI-1640 
alone (NS or nonstimulated), 3LL supernatants, or 3LL supernatants con-
taining 10 g/ml anti-PGE2 or isotype control. Arginase I was tested 48 h 
later via Western blot analysis. (B, C) MSCs (2  106) were cultured in 
RPMI 1640 (NS) or cocultured in transwells with 3LL cells (2  106) in the 
presence of increasing concentrations (M) of COX-1–specific (FR122047) 
and COX-2–specific (sc-58125) inhibitors. Arginase I expression was tested 
after 48 h of coculture via Western blot analysis, as was arginase activity 
via conversion of L-Arg to L-ornithine. *P  0.0001 when comparing MSCs 
cocultured with 3LL with MSCs cocultured with 3LL in the presence of 
sc-58125 (20 M).
 PROSTANOIDS INDUCE ARGINASE I IN TUMOR-BEARING MICE | Rodriguez et al.
 
934
 
EP4 signaling induces arginase I expression
 
PGE
 
2
 
 can bind to different EP receptors (EP1, EP2, EP3, EP4)
on target cells (18). The intracellular signaling pathways differ
substantially and may in part explain the wide array of effects
induced by PGE
 
2
 
. The EP1 receptor is coupled to intracellular
calcium, while EP2 and EP4 receptors signal by stimulating
adenylyl cyclase and cAMP. Signaling by EP3 receptor couples
different signaling pathways including Gi, Gs, and calcium.
MSCs strongly expressed EP2, EP3, and EP4, with low levels
of EP1, whereas 3LL cells expressed EP2 and EP3 (Fig. 6 A).
PGE
 
2
 
 analogues that differ in their affinity for EP receptors
were then used to determine which EP receptor could induce
arginase I in MSCs. Misoprostol at lower concentrations stim-
ulates EP2, EP3, and EP4, whereas sulprostone and 17-phenyl-
 

 
-trinor PGE
 
2
 
 are specific for EP1 and EP3. Butaprost is a
selective agonist for EP2, whereas PGE
 
1
 
 alcohol is a selective
agonist for EP3 and EP4. MSCs were stimulated for 24 h using
1 
 

 
M of each of the PGE
 
2
 
 agonists. Increased arginase activity
and arginase I expression were induced by PGE
 
1
 
 alcohol and
misoprostol, both being EP3 and EP4 agonists (Fig. 6, B and
C). Sulprostone and 17-phenyl-
 

 
-trinor, also EP3 agonists, did
not induce arginase, which suggests that EP4 may be the re-
ceptor that preferentially signals the induction of arginase I. As
described before, activation of EP4 induces increased cAMP
levels. Similarly, MSCs cocultured with 3LL tumor cells had an
increase in cAMP levels (unpublished data). Even though EP4
KO mice have been described previously, they were not avail-
able to the researchers to confirm this observation.
 
COX-2 inhibition blocks the induction of arginase I in vivo 
and has an antitumor effect
 
To test the role of COX-2 in the induction of arginase I in
vivo, tumor-bearing mice were injected with COX-2 inhib-
itor sc-58125 (5 mg/kg) or vehicle control (DMSO) every
other day in the contralateral side from the tumor, starting
on the day of tumor injection (1 
 

 
 10
 
6
 
 3LL cells). After 18 d,
tumors were excised and tested for arginase I expression.
COX-2 inhibitor sc-58125 completely blocked the induc-
tion of arginase I in the tumor (Fig. 7 A) and also decreased
tumor growth (P 
 

 
 0.01) (Fig. 7, B and C). The antitumor
effect induced by the COX-2 inhibitor in tumor-bearing
C57BL/6 mice was dependent on the presence of compe-
tent lymphocytes, as demonstrated by the loss of the antitu-
mor effect in C57BL/6 
 
Prkdc
 
scid
 
 mice (Fig. 7 C). In addition,
experiments performed in CD4
 
	
 
/
 
	
 
 and CD8
 
	
 
/
 
	
 
 mice sug-
gest that both CD4
 


 
 and CD8
 


 
 T cells contribute to the an-
titumor effect induced by inhibition of COX-2 (Fig. 7 D).
Furthermore, the antitumor effect induced by sc-58125 did
not appear to be mediated by an anti-angiogenic response,
because mice receiving sc-58125 or vehicle showed no ma-
Figure 5. COX-2 silencing in 3LL tumor cells blocks arginase I 
induction. (A) 3LL cells were transfected using COX-2 siRNA or an 
irrelevant siRNA probe as described in Material and methods. COX-2 
mRNA expression was determined via Northern blot analysis. (B, C) After 
24 h of transfection, 3LL cells (2  106) were cocultured with freshly 
isolated MSCs (2  106) using transwells, and arginase I expression and 
activity were tested in MSCs after 48 h. All experiments were repeated 
3 times. *P  0.005 when comparing MSCs cocultured with 3LL with 
MSCs cocultured with 3LL transfected with COX-2 siRNA.
Figure 6. EP4 activation induces arginase I in MSCs. (A) 3LL cells 
kept in culture and MSCs isolated from 3LL tumors were tested via Western 
blot analysis for EP receptor expression. (B, C) MSCs (2  106) were cultured 
in the presence of 1 M EP analogues for 24 h, after which arginase activity 
and arginase I expression were tested. White lines indicate that intervening 
lanes have been spliced out.
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jor differences in the expression of pro-angiogenic factor
VEGF and the metastasis marker E-cadherin (Fig. 7 E).
 
Arginase I is induced by tumor-derived COX-2
 
COX-2 and prostanoid production in the tumor could
come from the 3LL cells or from other host tissues such as
macrophages or endothelial cells. To determine the relative
contribution of tumor-derived COX-2 and host-derived
COX-2 in the induction of arginase I, we injected COX-2
knockout mice with 3LL tumor cells and measured arginase
I expression in MSCs. Arginase I was equally induced in
both wild-type and COX-2 knockout mice (Fig. 8), sug-
gesting that tumor-derived COX-2 and PGE
 
2
 
 produced by
the tumor cells is more important in arginase I induction
than endogenous expression of COX-2 and PGE2 by host
tissues. Furthermore, no major changes in COX-2 expres-
sion were observed in tumors excised from wild-type and
COX-2 knockout mice, as previously described (19).
DISCUSSION
Lung cancer remains the major cause of cancer-related deaths
in the United States (20). Although immunological-based
therapies have shown some success in other malignancies,
lung cancer has been largely unresponsive (21, 22). This might
be explained in part by the highly immunosuppressive mi-
croenvironment of lung tumors, which could induce a state of
immune tolerance, blocking the efficacy of cancer immuno-
therapies. We recently described the presence of MSCs pro-
ducing arginase I in murine and human lung carcinoma,
which induced major alterations in the T cell receptor expres-
sion and T cell function (5). However, the mechanisms lead-
ing to arginase I induction in MSCs were unknown.
Even though IL-4 and IL-13 induce arginase I in murine
peritoneal and bone marrow–derived macrophages, our
studies failed to show a role for these cytokines (Fig. S1) or
their receptors (not depicted) in the induction of arginase I
Figure 7. COX-2 inhibitor sc-58125 blocks arginase I induction in 
vivo. (A) Mice (n  10) were injected subcutaneously with 3LL cells (1  106) 
in the right flank and received subcutaneous injections of the COX-2 inhibitor 
sc-58125 (5 mg/kg) or DMSO (dilution vehicle) every other day for 18 d in 
the left flank. Tumor was excised and tumor single-cell suspensions were 
tested for arginase I and COX-2 via Western blot analysis. (B–D) Tumor 
volume was determined in tumor-bearing C57BL/6-Prkdcscid (n  8), CD4	/	 
(n  8), and CD8 	/	 (n  8) mice receiving sc-58125 or DMSO. (E) Single-cell 
suspensions from tumors were lysed and tested for VEGF and E-cadherin 
expression. One representative sample from eight different tumors is shown.
Figure 8. Arginase I is induced by tumor-derived COX-2. Arginase 
was tested in tumors harvested 18 d after tumor injection from COX-2 
knockout mice. One representative sample of two different tumors is shown.
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by 3LL lung carcinoma. Instead, the data demonstrate that
prostanoids produced by tumor cells induce and sustain argi-
nase I production in MSC-infiltrating tumors as well as peri-
toneal macrophages in vitro. The data also suggest that the
most likely prostanoid mediating this process is PGE2. PGE2
is generated by the metabolism of PGH2 by three different
PGESs: one cytosolic form (cPGES) and two microsomal-
associated forms (mPGES-1 and -2). mPGES-1 preferentially
metabolizes PGH2 derived from COX-2, while mPGES-2
has similar affinity for PGH2 derived from COX-1 and
COX-2 and is up-regulated in several carcinomas (23). 3LL
cells expressed mPGES-2 and cPGES, but not mPGES-1.
However, only the inhibition of COX-2, but not COX-1
(by pharmacological or genetic methods) inhibited arginase I
induction in MSCs by the tumor cells in vitro and in vivo.
Increasing evidence supports the multifaceted effect of
tumor-produced prostanoids on cancer progression. PGE2
not only enhances tumorigenesis by conferring a metastatic
phenotype, increasing resistance to apoptosis and stimulating
angiogenesis, it also impairs the host immune response.
PGE2 has been shown to decrease IL-12 and increase IL-10
production in dendritic cells and macrophages (24–26).
PGE2 may also influence a wide range of T cell functions,
including inhibition of T lymphocyte activation and prolif-
eration (27), promoting the development of a Th2 response
and inhibiting the production of the Th1 cytokines IL-2 and
interferon  (28). PGE2 produced by macrophages may also
decrease proliferation and inhibit T cell cytotoxic responses
(29, 30). However, macrophage-derived PGE2 is not playing
a role in the induction of arginase I, because the injection of
3LL in COX-2 knockout mice was similar to wild-type
mice bearing tumors. The multiplicity of effects caused by
PGE2 may be explained in part by the various receptors it
engages. PGE2 interacts with different isoforms of trans-
membrane G protein-coupled receptors. Four main PGE2
EP receptor subtypes have been identified (EP1, EP2, EP3,
and EP4), encoded by distinct genes, which use alternate and
in some cases opposing intracellular signaling pathways (31).
Our data suggest that signaling through EP4 may be respon-
sible for arginase I induction in MSCs. The distinguishing
feature of EP2 and EP4 receptors is their ability to stimulate
intracellular cAMP formation. MSCs cocultured with 3LL
had increased intracytoplasmic cAMP levels (unpublished
data); however, EP4 can also induce other signal transduc-
tion pathways in a cAMP-independent manner (32, 33).
Further evidence of the potential involvement of EP4 recep-
tor in other tumors such as colon cancer has come from the
use of an EP4-selective antagonist resulting in a decrease in
the number of aberrant crypt foci and polyps (34).
Our data show that prostanoids produced by COX-2
metabolism in 3LL tumor cells induces arginase I expression,
a potent mechanism of tumor evasion found in various mu-
rine tumor models in the lung and colon (2, 5). This obser-
vation is not limited to 3LL cells, because we have also
found a high expression of COX-2 and the ability to induce
arginase I expression in MSCs in SCC VII head and neck tu-
mors (Fig. S3), three different renal cell carcinoma lines, and
colon carcinoma MCA-38 (not depicted). Furthermore, in-
creased COX-2 expression and PGE2 production has been
reported in human colon carcinomas, breast cancer (35), re-
nal cell carcinoma (36), and lung carcinoma (37–39), which
has led to the testing of COX-2 inhibitors as a means for
cancer prevention. The observations presented here provide
a new explanation for the antitumor effects seen by COX 2
inhibitors. Aspirin, sulindac, and NS-398 decreased lung
cancer incidence in a dose–response manner in mice ex-
posed to tobacco-specific nitrosamine 4-(methylnitros-
amino)-1-(3-pyridyl)-1-butanone by inhibition of COX-2
expression and induction of apoptosis (40). Indomethacin
inhibited the accumulation of tumor cells in mouse lungs
and subsequent growth of lung metastases (41). Celecoxib, a
selective COX-2 inhibitor, dose-dependently inhibited pri-
mary tumor growth as well as the number and size of lung
metastases in 3LL cells and human colon carcinoma HT29
cells (42). Meloxicam, a preferential COX-2 inhibitor, in-
hibited PGE2 production and the growth of non–small cell
lung cancer cell lines (43). All of these studies strongly sup-
port the notion that blocking COX-2 inhibits tumor forma-
tion. It is therefore possible that one of the pathways for tu-
mor prevention induced by the use of COX-2 inhibitors
may be mediated by the inhibition of arginase I in MSCs.
An increased arginase activity has been described in pa-
tients with different types of tumors and can be produced by
certain tumors or MSCs (5, 44, 45). However, the mecha-
nisms by which arginase leads to tumor growth have been
poorly understood. Macrophages expressing arginase I in-
creased the production of polyamines, which increases tu-
mor proliferation (10). In addition, recent data published by
us and others show that infiltrating MSCs are the primary
producers of arginase I and are potent inhibitors of TCR ex-
pression and antigen-specific T cell responses in vivo (2, 5,
46). The depletion of L-Arg by MSCs blocks CD3 expres-
sion (5) and T cell receptor signaling, and also increases the
production of reactive oxygen species, which induce T cell
apoptosis (46). Therefore, the increase in arginase I expres-
sion may not only facilitate tumor growth by producing
more polyamines, but may also facilitate tumor escape by
blocking the immune response. In contrast, low levels of
L-Arg can also affect tumor growth in vitro by inducing tumor
cell proliferation arrest (47, 48). However, the mechanisms
by which low levels of L-Arg affect tumor growth in vivo
are unknown. We have found that the injection of exoge-
nous L-Arg without an arginase inhibitor in tumor-bearing
mice potentiated tumor growth (unpublished data).
The data found here may also open new approaches to
enhance the therapeutic efficacy of immunotherapy. Previ-
ous data have shown that inhibition of arginase I in vivo
with the arginase inhibitor Nor-NOHA prevented tumor
growth through an immunomediated mechanism (5). Here,
we described that blocking COX-2 can achieve a similar re-
JEM VOL. 202, October 3, 2005 937
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sponse. Furthermore, De Santo et al. (49) have also shown
that arginase inhibition using nitro-aspirin renders an anergic
mouse, responsive a tumor vaccine resulting in a therapeutic
antitumor response. In addition, inhibition of arginase can
boost T cell responses in human prostate tumors (50)
The importance of arginase-producing MSCs is not lim-
ited to cancer. The association of increased arginase activity
and T cell dysfunction was initially described in liver trans-
plantation and trauma patients. This process was reversed by
the enteral or parenteral supplementation of L-Arg (51). Argi-
nase production has also been described in models of chronic
infections by Helicobacter pylori (37, 52) and leishmaniasis (53,
54). In cancer patients (44, 45) the increased arginase activity
was thought to come from tumor cells metabolizing L-Arg to
produce polyamines to sustain rapid proliferation (10). How-
ever, as shown by Rodriguez et al. (5) in mice and more re-
cently by Zea et al. (36) in patients with renal cell carcinoma,
as well as Bronte et al. in prostate carcinoma (50), arginase
comes from MSCs circulating in peripheral blood and infil-
trating the tumors, respectively. However, Munder et al. (55)
have suggested that arginase I is also expressed in the granulo-
cytes of healthy individuals. We are currently studying
whether arginase I is differentially regulated in the granulo-
cytes of normal individuals and cancer patients.
Finally, the therapeutic promise of immunotherapy of
cancer using cytokines, activated T cells, or cancer vaccines
has been eclipsed by the presence of evasion mechanisms in
the tumor. Inhibition of the immune response by limiting
amino acid availability has now been described for tryp-
tophan and L-Arg. However, it is possible that blocking argi-
nase I through the careful use of COX-2 inhibitors and mon-
itoring the expression of arginase I will allow us to better use
the different immunotherapies at the time when tumor-
induced tolerance mediated by arginase I is blocked. How-
ever, it is important to consider that the mechanisms of eva-
sion may differ between the different types of tumors and will
need to be determined before the initiation of treatment.
MATERIALS AND METHODS
Cells and animals. Lewis lung carcinoma (3LL) cells, a murine lung car-
cinoma cell line (American Type Culture Collection), and SCC VII, a
squamous cell carcinoma cell line (provided by S. Strom, University of
Maryland, Baltimore, MD), were maintained in RPMI 1640 (BioWhittaker)
supplemented with 10% fetal calf serum (Hyclone), 25 mM Hepes (Gibco-
Invitrogen), 4 mM L-glutamine (BioWhittaker), and 100 U/ml of penicil-
lin/streptomycin (Gibco-Invitrogen). 6-wk-old female C57BL/6 mice,
C3H/HeJ (Harlan) mice, C57BL/6 Prkdcscid mice, C57BL/6-cd4tm1Knw
(CD4 KO) mice, C57BL/6-Cd8atm1Mak (CD8 KO) mice (The Jackson
Laboratory), and C57BL/6 COX-2 knockout mice (Taconic) were in-
jected subcutaneously with 1  106 3LL cells. Tumors were harvested at
different time points as indicated in Results. All experiments using animals
were approved by the LSU-IACUC and were performed following LSU
animal care facility guidelines.
Antibodies. Antibodies used included: COX-1 (H-62), COX-2 (M-19)
(Santa Cruz Biotechnology, Inc.), arginase I (Transduction-Becton Dickin-
son), cPGES, mPGES-1, mPGES-2, and EP1, EP2, EP3, and EP4 (Cayman
Chemical and Santa Cruz Biotechnology, Inc.). Positive controls included
murine kidney (EP1) and RAW 264.7 cells stimulated with 100 ng/ml LPS
(EP2, EP3, and EP4). VEGF was obtained from Santa Cruz Biotechnology,
Inc., and E-cadherin was obtained from Transduction-Becton Dickinson.
Reagents. Proteases including V8 protease, chymotrypsin, trypsin, and
proteinase K (Sigma-Aldrich) were used to determine the protein nature of
the 3LL cells factor that induced arginase I. Specific inhibitors of COX-1
(FR122047) (Calbiochem) (17) and COX-2 (sc-58125) (Calbiochem) (16)
were used in in vitro experiments or were injected subcutaneously in mice
every other day. Control mice were injected with DMSO. PGE2 agonists
included misoprostol, sulprostone, 17-phenyl--trinor PGE2, butaprost,
and PGE1 alcohol (Cayman Chemical).
siRNA probes. The constitutive expression of COX-1 and COX-2 in
3LL cells was silenced with chemically synthesized siRNAs. The transfec-
tion experiments were standardized using siRNA for GAPDH (Ambion)
based on the number of cells to be transfected (1  105), the volume of
transfection agent (Lipofectamine 2000, Invitrogen) and quantity of siRNA
(200 nM). Chemically synthesized siRNA sequences included: COX-1,
sense strand siRNA 1, 5-GGGAAGAAACAGUUACCAGtt-3, antisense
strand siRNA, 5-CUGGUAACUGUUUCUUCCCtt-3; COX-2, sense
strand siRNA, 5-GGAUUUGACCAGUAUAAGUtt-3, antisense strand
siRNA, 5-ACUUAUACUGGUCAAAUCCtg-3. The negative control
siRNA (Ambion) had no homology to known sequences from mice, rats,
or humans. The expression of the targeted gene was tested after 24, 48, and
72 h via Northern blot analysis. Cocultures using transwells of the siRNA-
transfected 3LL cells and MSCs were established 24 h after transfection.
MSCs were harvested after 48 h and tested for arginase I expression and ar-
ginase activity. 3LL cells were also collected to reconfirm the silencing of
COX enzymes. Controls included cocultures of MSCs with wild-type 3LL
cells as positive control and 3LL cells transfected with GAPDH siRNA or
the negative control siRNA purchased from Ambion.
Cell subset isolation from 3LL tumors. Tumors were removed from
mice under sterile conditions 14 d after tumor injection. Tumors were di-
gested with trypsin-EDTA (Invitrogen) for 3 h, and the single cell suspen-
sion was passed through a 40-m cell strainer (Becton Dickinson-Falcon).
To isolate tumor-associated MSCs, excised tumors were stained for CD11b,
CD16/CD32, and class II and separated with anti-FITC immunomagnetic
beads (Miltenyi Biotec) as described previously (5). Purity ranged between
95 and 99%.
Peritoneal macrophages purification. 6-wk-old female C57BL/6 mice
were used to isolate peritoneal macrophages as previously described (56).
After 2 d of culture in RPMI with 4% fetal bovine serum, unattached cells
were washed off and attached cells were used in cocultures.
PGE2 and PGE2 metabolites. PGE2 and its metabolite levels were tested
in supernatants and cytoplasmic extracts by EIA using kits from Cayman
Chemicals, following the vendor’s recommendations.
Ribonuclease protection assay. Five micrograms of RNA isolated using
TRIzol (Invitrogen) were tested for several cytokine expressions using ribo-
nuclease protection assay (BD PharMingen) following the vendor’s recom-
mendations. In brief, RNA were mixed with the templates (BD Bio-
sciences) and incubated at 90C allowing the temperature to decrease
slowing to 56C. Samples were then treated with RNase followed by pro-
teinase K and extracted using phenol-chloroform and precipitated using
ethanol. Samples were separated in polyacrylamide gel containing 8 M urea,
dried, and exposed to Kodak Biomax-MR films (Eastman Kodak).
Northern blot analysis. Two million cells were used for RNA extrac-
tion using lysis with TRIzol (Invitrogen) following the manufacturer’s spec-
ifications. Five micrograms of total RNA from each sample were electro-
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phoresed under denaturing conditions, blotted onto nytran membranes
(Schleicher & Schuell), and cross-linked by UV irradiation. Membranes
were prehybridized at 42C in ULTRAhyb buffer (Ambion) and hybridized
overnight with 106 cpm/ml of 32P-labeled probe. Probes for detection of
arginase I, COX-1, COX-2, and GAPDH (CLONTECH Laboratories,
Inc.) mRNA were labeled by random priming using a RediPrime Kit (GE
Healthcare) and [-32P] dCTP (3,000 Ci/mmol; NEN Life Science Prod-
ucts). Membranes were washed and subjected to autoradiography at 	70C
using Kodak Biomax-MR films (Eastman Kodak) and intensifying screens.
Western blot analysis. Cell extracts were obtained as previously de-
scribed (56). The expression of arginase I, COX-1, COX-2, EP receptors,
PGES, E-cadherin, VEGF, and GAPDH were detected by immunoblotting
using 30 g of cell extracts. Cytoplasmic extracts were electrophoresed in
10 or 8% Tris-Glycine gels (Novex), transferred to PVDF membranes, and
immunoblotted with the appropriate antibodies. The reactions were de-
tected using an electrochemiluminescence kit (GE Healthcare).
Arginase activity assay. Cell lysates (2 g) were tested for arginase activ-
ity by measuring the production of L-ornithine and urea from L-Arg (56).
In brief, cell lysates were added to 25 l of Tris-HCl (50 mM; pH 7.5) con-
taining 10 mM MnCl2. This mixture was heated at 55–60C for 10 min to
activate arginase. Then, a solution containing 150 l carbonate buffer (100
mM) (Sigma-Aldrich) and 50 l L-Arg (100 mM) was added and incubated
at 37C for 20 min. The hydrolysis reaction from L-Arg to L-ornithine was
identified via colorimetric assay after the addition of ninhydrin solution and
incubation at 95C for 1 h. In addition, the hydrolysis reaction from L-Arg
to urea was detected with diacetyl monoxime (Sigma) and incubation at
95C for 10 min.
Statistical analysis. Comparison of values for arginase activity, PGE2 lev-
els, and tumor volume was performed via one-way analysis of variance us-
ing the Graph Pad statistical program (Graph Pad).
Online supplemental material. Fig. S1 shows that the only cytokines
found in the 3LL tumor cells were mCSF and VEGF (A). However, increasing
concentrations of mCSF and VEGF did not maintain arginase I expression in
MSCs (B). Fig. S2 shows that addition of PGE2 (10 ng/ml) maintains arginase
I expression in MSCs. Fig. S3 shows that inhibition of COX-2 in SCC VII tu-
mor cells (sc-58125, 20 M) blocks arginase I induction in MSCs. Fig. S4
shows that inhibition of COX-2 activity and expression blocks arginase I in-
duction in peritoneal macrophages. Online supplemental material is available at
http://www.jem.org/cgi/content/full/jem.20050715/DC1.
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